LOS ANGELES, March 11, 2014 /PRNewswire/
-- ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC)
("ImmunoCellular" or the "Company") today announced that it
will hold its 2014 Annual Meeting of Stockholders on Friday, June 13, 2014. Because the expected
meeting date for the 2014 Annual Meeting represents a change of
more than thirty days from the anniversary of the Company's 2013
annual meeting of stockholders held on September 20, 2013, the Company has set a new
deadline for the receipt of stockholder proposals submitted
pursuant to Rule 14a-8 under the Securities Exchange Act of 1934,
as amended (the "Exchange Act") for inclusion in the Company's
proxy materials for the 2014 Annual Meeting. In order to be
considered timely, such proposals must comply with the stockholder
proposal requirements set forth in the Company's Bylaws and be
received by the Company on or before April
15, 2014 at its principal office at 23622 Calabasas Road,
Suite 300, Calabasas, California
91302, Attention: Corporate Secretary.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular is conducting a Phase II trial of its
lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine
targeting ovarian cancer antigens and cancer stem cells. To learn
more about ImmunoCellular, please visit www.imuc.com.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Photo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
SOURCE ImmunoCellular Therapeutics, Ltd.